CAR T cell therapy targets key mutation driving rare blood cancers

A caller signifier of CAR T-cell therapy has been designed to find and destruct the cancer-driving stem cells liable for a radical of humor cancers known arsenic myeloproliferative neoplasms (MPNs), portion leaving steadfast humor cells unharmed, according to caller probe led by UCL and University of Oxford researchers.